Key result
Systemic ET(B) receptor blockade with A-192621 produced sustained hypertension in conscious mice that was reversed or prevented by the ET(A) antagonist atrasentan.
Why the study?
Does ET(A) and ET(B) receptor blockade alter basal blood pressure and ET(B) blockade-induced hypertension in conscious mice?
Does ET(A) and ET(B) receptor blockade alter basal blood pressure and ET(B) blockade-induced hypertension in conscious mice?
ET(A) and ET(B) receptors play a physiologically relevant role in basal blood pressure regulation, and ET(A) receptors maintain the hypertension produced by ET(B) blockade in mice.
Answers are grounded in this paper and cite their sources.
Preclinical ET(B) blockade data warrant caution in models; leaves open ET(A) targeting for human hypertension.
The net contribution of endothelin type A (ET(A)) and type B (ET(B)) receptors in blood pressure regulation in humans and experimental animals, including the conscious mouse, remains undefined. Thus we assessed the role of ET(A) and ET(B) receptors in the control of basal blood pressure and also the role of ET(A) receptors in maintaining the hypertensive effects of systemic ET(B) blockade in telemetry-instrumented mice. Mean arterial pressure (MAP) and heart rate were recorded continuously from the carotid artery and daily (24 h) values determined. At baseline, MAP ranged from 99 +/- 1 to 101 +/- 1 mmHg and heart rate ranged between 547 +/- 15 and 567 +/- 19 beats/min (n = 6). Daily oral administration of the ET(B) selective antagonist A-192621 [10 mg/kg twice daily] increased MAP to 108 +/- 1 and 112 +/- 2 mmHg on days 1 and 5, respectively. Subsequent coadministration of the ET(A) selective antagonist atrasentan (5 mg/kg twice daily) in conjunction with A-192621 (10 mg/kg twice daily) decreased MAP to baseline values on day 6 (99 +/- 2 mmHg) and to below baseline on day 8 (89 +/- 3 mmHg). In a separate group of mice (n = 6) in which the treatment was reversed, systemic blockade of ET(B) receptors produced no hypertension in animals pretreated with atrasentan, underscoring the importance of ET(A) receptors to maintain the hypertension produced by ET(B) blockade. In a third group of mice (n = 10), ET(A) blockade alone (atrasentan; 5 mg/kg twice daily) produced an immediate and sustained decrease in MAP to values below baseline (baseline values = 101 +/- 2 to 103 +/- 2 mmHg; atrasentan decreased pressure to 95 +/- 2 mmHg). Thus these data suggest that ET(A) and ET(B) receptors play a physiologically relevant role in the regulation of basal blood pressure in normal, conscious mice. Furthermore, systemic ET(B) receptor blockade produces sustained hypertension in conscious telemetry-instrumented mice that is absent in mice pretreated with an ET(A) antagonist, suggesting that ET(A) receptors maintain the hypertension produced by ET(B) blockade.
No takes yet. Share an insight, caveat, or question.
Fryer et al. (2006) studied Blood pressure regulation (n=22). ET(B) selective antagonist A-192621 and ET(A) selective antagonist atrasentan vs. Baseline was evaluated on Mean arterial pressure (MAP). Systemic ET(B) receptor blockade with A-192621 produced sustained hypertension in conscious mice that was reversed or prevented by the ET(A) antagonist atrasentan.
Synapse has enriched 10 related papers. Consider them for comparative context: